Lantus vs Basaglar vs Semglee: Biosimilar Insulin Guide

Understanding Biosimilar Insulins: Lantus, Basaglar, and Semglee

If your doctor has prescribed a long-acting insulin or suggested switching from one brand to another, you may have encountered the names Lantus, Basaglar, and Semglee. All three contain insulin glargine 100 units/mL, but there are important distinctions worth understanding before making any changes to your regimen.

What Is Insulin Glargine?

Insulin glargine is a long-acting, basal insulin designed to provide a steady, 24-hour background level of insulin coverage. It helps control blood sugar levels between meals and overnight. Unlike rapid-acting insulins, it has no pronounced peak, which reduces the risk of sudden hypoglycemia.

Lantus: The Original Brand

Lantus (made by Sanofi) was the first insulin glargine approved by the FDA in 2000. It became one of the most widely prescribed basal insulins in the world. Lantus is available in both a vial and a SoloStar prefilled pen. Because it has decades of real-world data behind it, many endocrinologists and patients remain comfortable with it. However, its brand-name price tag can be significantly higher than its biosimilar counterparts.

Basaglar: The First Biosimilar Follow-On

Basaglar (made by Eli Lilly and Boehringer Ingelheim) was approved by the FDA in 2015 and launched in 2017. It was classified as a follow-on biological product rather than an interchangeable biosimilar at the time of its approval. Basaglar is only available in the KwikPen prefilled format — there is no vial option — which can be a limitation for patients who prefer syringes or who use insulin pumps.

Semglee: The First Interchangeable Biosimilar

Semglee (made by Viatris and Biocon) made history in 2021 as the first FDA-designated interchangeable biosimilar insulin. This distinction means pharmacists can legally substitute Semglee for Lantus without a new prescription from the doctor, depending on state laws. Semglee is available in both a vial and a prefilled pen, offering greater flexibility. It is typically the most affordable of the three options.

Key Differences at a Glance

• Active ingredient: All three contain insulin glargine 100 units/mL
• Manufacturer: Lantus (Sanofi), Basaglar (Eli Lilly), Semglee (Viatris/Biocon)
• Formulation: Lantus and Semglee offer vials and pens; Basaglar is pen-only
• FDA status: Semglee is the only interchangeable biosimilar; Basaglar is a follow-on product
• Cost: Semglee is generally the lowest cost, followed by Basaglar, then Lantus

Are They Equally Effective?

Clinical studies have shown that all three products demonstrate comparable safety and efficacy profiles. The FDA's interchangeable designation for Semglee means it has met rigorous standards proving it produces the same clinical result as Lantus in any given patient. That said, always consult your healthcare provider before switching insulins, as individual responses can vary and dose adjustments may occasionally be needed.

Cost and Insurance Considerations

One of the biggest drivers behind biosimilar insulin adoption is cost. Semglee's list price is significantly lower than Lantus, which can matter enormously for uninsured or underinsured patients. Many insurance plans now prefer biosimilars on their formularies, so your out-of-pocket cost may actually be lower with Semglee or Basaglar even if you were originally prescribed Lantus. For detailed guidance on managing insulin costs and coverage options, resources like mdsdiabetes.com can provide up-to-date, patient-friendly information.

Bottom Line

Lantus, Basaglar, and Semglee are all effective long-acting insulin options for people with type 1 or type 2 diabetes. Your best choice depends on your insurance coverage, cost concerns, delivery device preference, and your doctor's recommendation. Never switch insulins without speaking to your healthcare team first — even small changes in formulation or concentration can affect blood sugar control.